Reply to Can Lu and Xiao Guan's Letter to the Editor re: Marko Babjuk. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.01.022

Abstract

It is apparent that before neoadjuvant immunotherapy is used as a standard of care we must improve patient selection. The individual approach, which may consist of NAC, neoadjuvant ICI, or immediate radical cystectomy, will be chosen according to criteria determined from pathology, molecular subtyping, and biomarker analysis results.

This is also the best way to reasonably minimize the financial burden of a patient's treatment.

Keywords

• neoadjuvant immunotherapy
• radical cystectomy
• metastatic disease
• economic burden